(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 December 2010 (29.12.2010)

PCT

(10) International Publication Number
WO 2010/151216 A1

(51) International Patent Classification:
A61K 31/4439 (2006.01) *A61P 19/02* (2006.01)
A61K 9/24 (2006.01) *A61P 29/00* (2006.01)

(21) International Application Number:
PCT/SE2010/050712

(22) International Filing Date:
23 June 2010 (23.06.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/220,420	25 June 2009 (25.06.2009)	US
61/225,970	16 July 2009 (16.07.2009)	US
61/310,525	4 March 2010 (04.03.2010)	US

(71) Applicants *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE). **POZEN Inc.** [US/US]; 1414 Raleigh Road, Chapel Hill, NC 27517 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **AULT, Brian** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **HWANG, Clara** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **ORLEMANS, Everardus** [NL/US]; POZEN Inc., 1414 Raleigh Road, Chapel Hill, NC 27517 (US). **PLACHETKA, John R.** [US/US]; POZEN Inc., 1414 Raleigh Road, Chapel Hill, NC 27517 (US). **SOSTEK, Mark** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2010/151216 A1

(54) **Title**: METHOD FOR TREATING A PATIENT AT RISK FOR DEVELOPING AN NSAID-ASSOCIATED ULCER

(57) **Abstract**: The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof. The unit dose is designed to release at least a part of the esomeprazole independent of pH (e.g. at a pH of 0 or more) whereas the naproxen is not released until the pH or the surrounding medium is 3.5 or higher.